Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stadler

Showing results (631-640 of 644) with videos related to

Pageof 65
Sort By:
The Prostate|November 15, 2023
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectivenessChanning J Paller, Pedro C Barata, Justin Lorentz, et al.
Optics Express|May 13, 2009
Digital in-line holography with femtosecond VUV radiation provided by the free-electron laser FLASHAxel Rosenhahn, Florian Staier, Thomas Nisius, et al.
Future Oncology (London, England)|April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Blood Advances|February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemiaAthalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Physical Review Letters|March 5, 2009
Coherent-pulse 2D crystallography using a free-electron laser x-ray sourceA P Mancuso, A Schropp, B Reime, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
The New England Journal of Medicine|August 21, 2024
Belzutifan versus Everolimus for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Katriina Peltola, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Clinical Pharmacology and Therapeutics|April 12, 2017
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug PrescribingP H O'Donnell, N Wadhwa, K Danahey, et al.
Pageof 65

Showing results (631-640 of 644) with videos related to

Sort By:
Pageof 65
The Prostate|November 15, 2023
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectivenessChanning J Paller, Pedro C Barata, Justin Lorentz, et al.
Optics Express|May 13, 2009
Digital in-line holography with femtosecond VUV radiation provided by the free-electron laser FLASHAxel Rosenhahn, Florian Staier, Thomas Nisius, et al.
Future Oncology (London, England)|April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Blood Advances|February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemiaAthalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Physical Review Letters|March 5, 2009
Coherent-pulse 2D crystallography using a free-electron laser x-ray sourceA P Mancuso, A Schropp, B Reime, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
The New England Journal of Medicine|August 21, 2024
Belzutifan versus Everolimus for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Katriina Peltola, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Clinical Pharmacology and Therapeutics|April 12, 2017
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug PrescribingP H O'Donnell, N Wadhwa, K Danahey, et al.
Pageof 65